The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...
DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.
We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...
Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.
It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...
Revealed at the Brussels Motor Show, the Intensa special edition is available in the United States of America for the 2025 model year from 44,495 dollars. The advertised price applies to the Alfa ...
Alfa Laval is setting up a state-of-the-art Food Innovation Centre in Copenhagen, Denmark to address global food challenges. The facility will support food producers in overcoming the escalating ...
Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].
Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.
Denali Therapeutics Inc. DNLI announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, tividenofusp alfa (DNL310), for the treatment of individuals with ...